ATRX Loss in the Development and Prognosis of Conjunctival Melanoma

Jolique A van Ipenburg, Quincy C C van den Bosch, Dion Paridaens, Hendrikus J Dubbink, Emine Kiliç, Nicole Naus, Robert M Verdijk, Rotterdam Ocular Melanoma Study Group

Research output: Contribution to journalArticleResearchpeer-review


Metastatic disease is linked to TERT promoter mutations in conjunctival melanomas (CM). Both TERT promoter and ATRX mutations are associated with faulty telomere maintenance. This study aimed to determine the prognostic value of ATRX loss in conjunctival melanocytic lesions. Eighty-six conjunctival melanocytic lesions from the Rotterdam Ocular Melanoma Study group were collected. ATRX status and TERT promoter status were determined using immunohistochemical staining and molecular diagnostics, respectively. None of the nevi (n = 16) and primary acquired melanosis (PAM) without atypia (n = 6) showed ATRX loss. ATRX loss was found in 2/5 PAM with atypia without CM and in 8/59 CM. No cases with a TERT promoter mutation (n = 26) showed ATRX loss. Eight/eleven metastatic CM harbored a TERT promoter mutation, two other metastatic CM showed ATRX loss and one metastatic case showed no TERT promoter/ATRX alterations. In conclusion ATRX loss and TERT promoter mutations are only found in (pre)malignant conjunctival melanocytic lesions, with most metastatic cases harboring one of these alterations, suggesting that both alterations are associated with adverse behavior. Similar to TERT promoter mutations, ATRX loss may be used as a diagnostic tool in determining whether a conjunctival melanocytic lesion is prone to having an adverse course.

Original languageEnglish
Article number12988
JournalInternational Journal of Molecular Sciences
Issue number16
Publication statusPublished - 20 Aug 2023


Dive into the research topics of 'ATRX Loss in the Development and Prognosis of Conjunctival Melanoma'. Together they form a unique fingerprint.

Cite this